BioSpace News Archive

Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, reported its financial results for the quarter and year ended December 31, 2022, and provided a corporate update.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.

Sensible Biotechnologies, an early stage biotechnology company, announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity.

Theratechnologies Inc. announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12, 2023.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference (RNAi) therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH).

Soligenix, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file (RTF) letter previously issued regarding the Company’s new drug application (NDA) for HyBryte™ (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, where it has successfully demonstrated statistically significant results in a Phase 3 clinical trial.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, will release first quarter 2023 financial results on Wednesday, April 26, 2023, prior to the market open.

NewAmsterdam Pharma Company N.V., a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the upcoming presentation of a case study, Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, on Sunday, April 23rd at 8:30 am (GMT+2).

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”) today announced a clinical collaboration with BeiGene. to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors.